Jupiter, FL — [November 2025] — Myosin Therapeutics, Inc. announced today that Courtney Miller, PhD, Chief Executive Officer and co-founder, and Karen Smith, MD, PhD, Chief Medical Officer, will attend the 2025 Society for Neuro-Oncology (SNO) Annual Meeting this November. While at SNO, Dr. Miller and Dr. Smith will meet with investigators, clinical partners, patient-advocacy leaders, and other stakeholders to discuss Myosin’s pipeline and ongoing clinical activities, including the company’s Phase 0/1b study in glioblastoma (GBM), NCT07185880. 

“Neuro-oncology urgently needs new, mechanism-based approaches,” said Dr. Courtney Miller, Chief Executive Officer. “SNO brings together the clinicians, researchers, and advocates who can accelerate those approaches from bench to bedside. We look forward to productive discussions about our clinical strategy and how MT-125 may help patients with GBM.” 

“My focus at SNO will be pragmatic clinical execution, site readiness, patient selection, and endpoints that truly matter to patients and physicians,” added Dr. Karen Smith, Chief Medical Officer. “We’re eager to collaborate with centers of excellence to ensure our trials are designed and conducted to the highest standards.” 

During the meeting, Myosin leadership will provide updates on: 

  • MT-125 (GBM): Ongoing clinical development in malignant gliomas, including enrollment progress and operational readiness across participating sites associated with NCT07185880. Activities at SNO will include working sessions with Mayo Clinic site Principal Investigators who will serve as clinical sites for the trial (Rochester, Scottsdale, and Jacksonville), covering site-initiation timelines, pharmacy and central-lab readiness, imaging protocol harmonization, biospecimen workflows, and patient referral pathways. 
  • Broader Pipeline: Programs targeting molecular motor proteins across oncology and CNS indications, with an emphasis on translational plans, partnerships, and upcoming milestones. 

Organizations interested in scheduling time with Myosin Therapeutics at SNO 2025 may reach out via contact@myosintherapeutics.com. 

About Myosin Therapeutics 

Myosin Therapeutics is a biotechnology company based in Jupiter, Florida, advancing first-in-class therapies for oncology and central nervous system disorders by targeting molecular nanomotor